Could ePRO Be The New Standard In Health Reimbursement?
Developing innovative drugs takes time, with an average of 9.1 years between the first-in-human trial and regulatory approval. Early-stage trials average even longer at nearly a decade, so many companies do not consider their marketing and sales strategies. Recently, however, early-phase protocols have been collecting patient-reported outcomes (PROs) not only to get regulatory approval but to demonstrate value to public and private payers.
VIEW THE ARTICLE! Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader X
Subscribe to Clinical Leader